Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 2/20 | 0.55 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | PPARG | P37231 | 1/20 | 0.52 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.52 |
| ▸ | ITGAV | P06756 | 1/20 | 0.52 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.50 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8500653 | 0.94 | ITGB3 (0.60) | ITGB3ITGA2BLMNAPPARGITGB1 | |
| SCHEMBL7450519 | 0.91 | PPARG (0.65) | ITGB3ITGA2BLMNAPPARGITGB1 | |
| SCHEMBL7373419 | 0.88 | ITGB3 (0.66) | ITGB3ITGA2BPPARGITGB1ITGAV | |
| SCHEMBL7380108 | 0.86 | LMNA (0.46) | ITGB3ITGA2BLMNAPPARGITGB1 | |
| SCHEMBL7380405 | 0.85 | F10 (0.58) | ITGB3ITGA2BPPARGITGB1ITGAV | |
| SCHEMBL7303034 | 0.85 | NR1H4 (0.54) | ITGB3ITGA2BITGB1ITGAVITGB5 | |
| SCHEMBL7856521 | 0.85 | PPARG (0.60) | ITGB3ITGA2BLMNAPPARGITGB1 | |
| SCHEMBL7856536 | 0.85 | LMNA (0.54) | ITGB3ITGA2BLMNAHDAC3HDAC4 | |
| SCHEMBL7861970 | 0.84 | ITGB3 (0.76) | ITGB3ITGA2BPPARGITGB1ITGAV | |
| SCHEMBL7453096 | 0.84 | LMNA (0.48) | LMNAHDAC3HDAC4HDAC1HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0891325-B1 | PARA-SUBSTITUTED PHENYLPROPANOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | SEARLE & CO (US) | 2002-02-06 | — | — | EP | claimed |
| EP-1157985-A1 | Para- substituted phenylene derivatives and their use as integrin antagonists | G.D. SEARLE & CO. (US) | 2001-11-28 | — | — | EP | claimed |
| US-6251944-B1 | (VITRONECTIN RECEPTOR) INTEGRIN ANTAGONIST, USEFUL FOR TREATING ANGIOGENESIS, TUMOR GROWTH, TUMOR METASTASIS, OSTEOPOROSIS AND HUMORAL HYPERCALCEMIA OF MALIGNANCY | G. D. SEARLE & COMPANY | 2001-06-26 | — | — | US | claimed |
| EP-0891325-A1 | PARA-SUBSTITUTED PHENYLPROPANOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | G.D. SEARLE & CO. (US) | 1999-01-20 | — | — | EP | claimed |
| WO-1997036859-A1 | PARA-SUBSTITUTED PHENYLPROPANOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | G.D. SEARLE & CO. (US) | 1997-10-09 | — | — | WO | claimed |
| EP-0891325-B1 | PARA-SUBSTITUTED PHENYLPROPANOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | SEARLE & CO (US) | 2002-02-06 | — | — | EP | disclosed |
| EP-1157985-A1 | Para- substituted phenylene derivatives and their use as integrin antagonists | G.D. SEARLE & CO. (US) | 2001-11-28 | — | — | EP | disclosed |
| US-6251944-B1 | (VITRONECTIN RECEPTOR) INTEGRIN ANTAGONIST, USEFUL FOR TREATING ANGIOGENESIS, TUMOR GROWTH, TUMOR METASTASIS, OSTEOPOROSIS AND HUMORAL HYPERCALCEMIA OF MALIGNANCY | G. D. SEARLE & COMPANY | 2001-06-26 | — | — | US | disclosed |
| EP-0891325-A1 | PARA-SUBSTITUTED PHENYLPROPANOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | G.D. SEARLE & CO. (US) | 1999-01-20 | — | — | EP | disclosed |
| WO-1997036859-A1 | PARA-SUBSTITUTED PHENYLPROPANOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | G.D. SEARLE & CO. (US) | 1997-10-09 | — | — | WO | disclosed |